Study guide

2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

Key Takeaways Explain This Topic AI

The 2025 AHA post-arrest guidelines target an SpO2 of 90%–98% (PaO2 about 60–105 mmHg), normocapnia (PaCO2 35–45 mmHg) and a MAP of at least 65 mmHg, avoiding both hypoxemia and hyperoxia.

For adults who do not follow commands after ROSC, the 2025 AHA guidelines recommend deliberate temperature control between 32°C and 37.5°C (Class 1) for at least 36 hours (Class 2a), with active fever prevention.

Shivering dramatically increases metabolic demand and oxygen consumption; it must be managed via a stepwise protocol combining surface counter-warming, scheduled acetaminophen, magnesium sulfate, buspirone, dexmedetomidine, opioids, and reserving neuromuscular blockers for refractory cases under continuous EEG monitoring.

Hypothermia markedly alters pharmacokinetics by decreasing cytochrome P450 metabolism and drug clearance, while causing intracellular electrolyte shifts (hypokalemia during cooling and life-threatening rebound hyperkalemia during rewarming if potassium infusions are not discontinued).

Neuroprognostication should be multimodal and delayed until at least 72 hours after return to normothermia, because sedatives and neuromuscular blockers clear slowly after hypothermia.

Last updated: October 2026

2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

The return of spontaneous circulation (ROSC) marks the transition from acute cardiopulmonary resuscitation to the complex, multidisciplinary phase of post-cardiac arrest care. Survivors of cardiac arrest suffer from post-cardiac arrest syndrome (PCAS) , a multifaceted pathophysiological state characterized by post-arrest brain injury, myocardial stunning, systemic ischemia-reperfusion response, and persistent precipitating pathology. Emergency medicine pharmacists play an essential role in optimizing oxygenation, hemodynamics, Targeted Temperature Management (TTM), shivering suppression, and navigating hypothermia-induced pharmacokinetic changes.

Initial Cardiopulmonary and Hemodynamic Optimization

Following ROSC, immediate management focuses on systematic physiological stabilization to prevent secondary neurological and myocardial injury:

1. Oxygenation Targets: Avoiding Hypoxia and Hyperoxia

Target S p O 2 SpO_2 Sp O 2 ​ : 90% to 98% in the 2025 AHA guidelines (PaO2 roughly 60 to 105 mmHg). The 2025 ESICM guideline uses a slightly higher floor of 94% to 98%, which is sensible when pulse oximetry may overestimate saturation, such as in patients with darker skin.

Danger of Hypoxia ( S p O 2 < 92 % SpO_2 < 92\% Sp O 2 ​ < 92% or P a O 2 < 60 mmHg PaO_2 < 60\text{ mmHg} P a O 2 ​ < 60 mmHg ) : Precipitates recurrent cardiac arrest and exacerbates ischemic neuronal apoptosis.

Danger of Hyperoxia ( P a O 2 > 300 mmHg PaO_2 > 300\text{ mmHg} P a O 2 ​ > 300 mmHg ) : Exposing ischemic-reperfused brain tissue to supraphysiologic oxygen tensions generates cytotoxic reactive oxygen species (ROS) , accelerates membrane lipid peroxidation, triggers cerebral arteriolar vasoconstriction, and directly worsens post-resuscitation functional recovery.

2. Ventilation Targets: Normocarbia

Target P a C O 2 PaCO_2 P a C O 2 ​ : 35 to 45 mmHg (or end-tidal C O 2 35 to 40 mmHg CO_2\text{ }35\text{ to }40\text{ mmHg} C O 2 ​ 35 to 40 mmHg ).

Danger of Hypocapnia ( P a C O 2 < 35 mmHg PaCO_2 < 35\text{ mmHg} P a C O 2 ​ < 35 mmHg ) : Hyperventilation causes marked cerebral vasoconstriction, drastically reducing cerebral blood flow and inducing secondary cerebral ischemia.

Danger of Hypercapnia ( P a C O 2 > 45 mmHg PaCO_2 > 45\text{ mmHg} P a C O 2 ​ > 45 mmHg ) : Induces cerebral vasodilation, increasing intracranial pressure (ICP) in the setting of post-ischemic cerebral edema, while worsening respiratory acidosis.

3. Hemodynamic Targets

Blood Pressure Goals : Maintain MAP ≥ 65 mmHg \ge 65\text{ mmHg} ≥ 65 mmHg (frequently targeting ≥ 65 to 80 mmHg \ge 65\text{ to }80\text{ mmHg} ≥ 65 to 80 mmHg in patients with chronic hypertension to preserve cerebral perfusion pressure given impaired autoregulation) and systolic blood pressure ≥ 90 mmHg \ge 90\text{ mmHg} ≥ 90 mmHg .

First-Line Vasopressor : Norepinephrine continuous IV infusion ( 0.05 to 0.5 mcg/kg/min 0.05\text{ to }0.5\text{ mcg/kg/min} 0.05 to 0.5 mcg/kg/min ). Norepinephrine provides potent alpha-1 vasoconstriction to restore perfusion pressure along with modest beta-1 support.

Post-Arrest Myocardial Dysfunction : Reversible ischemic myocardial stunning occurs in > 50 % >50\% > 50% of post-ROSC patients. If low cardiac output or persistent shock persists despite norepinephrine, add dobutamine ( 2.5 to 10 mcg/kg/min 2.5\text{ to }10\text{ mcg/kg/min} 2.5 to 10 mcg/kg/min ) or substitute/add epinephrine ( 0.05 to 0.3 mcg/kg/min 0.05\text{ to }0.3\text{ mcg/kg/min} 0.05 to 0.3 mcg/kg/min ).

4. Emergent Coronary Angiography

Immediate emergent cardiac catheterization is indicated for all post-ROSC adult patients who demonstrate ST-segment elevation myocardial infarction (STEMI) on their post-resuscitation 12-lead ECG, or those with refractory cardiogenic shock without an obvious non-cardiac cause, regardless of whether the patient is comatose .

Targeted Temperature Management (TTM): Evidence & Protocols

Targeted Temperature Management remains the cornerstone of neuroprotection for comatose adult patients with ROSC following cardiac arrest.

Candidate Selection & Temperature Target Selection

Indications : All comatose adults (failing to follow verbal commands) after cardiac arrest, regardless of initial rhythm (shockable or non-shockable) or arrest location (OHCA or IHCA).

Target Temperature Range : The 2025 AHA guidelines recommend deliberate temperature control with a target between 32°C and 37.5°C (Class 1). They no longer require the older 32°C–36°C range, reflecting the TTM-2 result that hypothermia offered no benefit over controlled normothermia. Prehospital cooling with cold IV fluids is not recommended.

Key Clinical Evidence (TTM-1 and TTM-2 Trials)

TTM-1 Trial (2013) : Compared hypothermia at 33°C versus 36°C in 950 OHCA patients and found no significant difference in all-cause mortality or neurological outcome at 6 months.

TTM-2 Trial (2021) : Compared hypothermia at 33°C versus targeted normothermia (early treatment of body temperature ≥ 37.8 ° C \ge 37.8°\text{C} ≥ 37.8° C using surface/intravascular cooling devices) in 1,900 OHCA patients. The trial found no difference in 6-month mortality (50% vs. 48%) or functional disability. However, the trial strictly mandated active feedback cooling devices to prevent fever in the normothermia arm.

Core Consensus : Fever ( > 37.8 ° C >37.8°\text{C} > 37.8° C ) is neurotoxic. Post-cardiac arrest hyperthermia drives cerebral metabolic rate, elevates ICP, accelerates apoptosis, and independently worsens mortality. Whether 33°C, 36°C, or 37.5°C is targeted, strict active temperature control must be maintained.

Protocol Duration and Rewarming Phase

Maintenance Phase : The 2025 AHA guidelines suggest maintaining temperature control for at least 36 hours (Class 2a), using closed-loop feedback surface pads or intravascular cooling catheters with continuous core temperature monitoring (esophageal or bladder probe).

Controlled Rewarming Phase : Rewarm slowly and precisely at a controlled rate of 0.25°C to 0.5°C per hour . Rapid rewarming triggers severe rebound intracranial hypertension, peripheral vasodilation with profound shock, and fatal hyperkalemia.

Fever Prevention : Fever worsens brain injury. The 2021 ERC-ESICM guideline advised preventing fever ( > 37.7 ° C >37.7°\text{C} > 37.7° C ) for at least 72 hours, and the 2025 ESICM update recommends active fever prevention for 36 to 72 hours in patients who remain comatose.

Stepwise Shivering Management Protocol

Shivering is the body's primary homeostatic response to cold, initiated when preoptic hypothalamic thermal sensors detect core temperatures below the shivering threshold (~36.5°C). Shivering increases metabolic rate and whole-body oxygen consumption by 200% to 500% , increases carbon dioxide production, and elevates intracranial pressure, completely abolishing the neuroprotective benefits of TTM.

Bedside Shivering Assessment Scale (BSAS)

0 (None) : No shivering detected on palpation.

1 (Mild) : Shivering localized to neck or thorax; visible only on palpation.

2 (Moderate) : Visible muscle tremor of extremities, pectoralis, or jaw.

3 (Severe) : Generalized, vigorous muscle shaking involving entire body.

Multimodal Stepwise Shivering Algorithm

Loading diagram...

Tier 1 (Non-Pharmacologic & Non-Sedating Baseline) :

Surface Counter-Warming : Wrap hands, feet, and distal extremities in warm socks, gloves, or convective warm-air blankets. Tricking cutaneous thermoreceptors reduces hypothalamic afferent shivering triggers without altering core cooling.

Acetaminophen : 1 g IV or enteral every 6 hours scheduled.

Magnesium Sulfate : IV infusion targeting a serum magnesium level of 3.0 to 4.0 mg/dL (1.2 to 1.6 mmol/L). Magnesium acts centrally to lower the shivering threshold and promotes peripheral vasodilation.

Tier 2 (Centrally Acting / Light Sedatives) :

Buspirone : 30 mg enterally every 8 hours. A 5 -HT 1 A 5\text{-HT}_{1A} 5 -HT 1 A ​ partial agonist that synergistically lowers the shivering threshold without sedation or respiratory depression.

Dexmedetomidine : Continuous IV infusion at 0.2 to 1.5 mcg/kg/hour. An alpha-2 adrenergic agonist that lowers the shivering threshold; monitor for dose-dependent bradycardia and hypotension.

Tier 3 (Opioids) :

Fentanyl : Continuous infusion 25 to 100 mcg/hour.

Meperidine : 25 to 50 mg IV push or continuous infusion. Meperidine uniquely lowers the shivering threshold through kappa-opioid and alpha-2 agonism. Safety Warning : Its neurotoxic metabolite, normeperidine , accumulates in renal impairment, lowering the seizure threshold.

Tier 4 (Neuromuscular Blockade - NMB) :

Cisatracurium ( 1 to 3 mcg/kg/min 1\text{ to }3\text{ mcg/kg/min} 1 to 3 mcg/kg/min ) or Rocuronium ( 0.3 to 0.6 mg/kg/hour 0.3\text{ to }0.6\text{ mg/kg/hour} 0.3 to 0.6 mg/kg/hour ) continuous infusion or boluses. Reserved exclusively for refractory shivering.

MANDATORY Requirement : Patients receiving paralytics must undergo continuous electroencephalography (cEEG) because neuromuscular blockade masks the peripheral motor manifestations of status epilepticus!

  • Altered Pharmacokinetics and Electrolyte Shifts in Hypothermia
  • Pharmacokinetic Derangements

Moderate hypothermia (32°C to 34°C) profoundly alters drug absorption, distribution, metabolism, and excretion:

Hepatic Clearance : Hypothermia impairs cytochrome P450 enzyme activity (CYP3A4, CYP2D6, CYP2C19) by 7% to 11% per 1°C drop below 37°C . Clearance of sedatives (midazolam, propofol), opioids (fentanyl), and paralytics (rocuronium, vecuronium) is reduced by 25% to 50%, prolonging elimination half-lives and causing severe drug accumulation.

Renal Clearance : Decreased renal perfusion and cold diuresis delay clearance of renally eliminated drugs.

Electrolyte Dynamics: Cooling vs. Rewarming

Phase Electrolyte Movement Expected Serum Changes Pharmacotherapy Action Required

Induction & Cooling Potassium, magnesium, and phosphate shift intracellularly ; cold-induced tubular diuresis. Hypokalemia, hypomagnesemia, hypophosphatemia. Replete conservatively; maintain K+ ≥ 3.5 mEq/L \ge 3.5\text{ mEq/L} ≥ 3.5 mEq/L , Mg ≥ 3.0 mg/dL \ge 3.0\text{ mg/dL} ≥ 3.0 mg/dL . Avoid aggressive potassium over-repletion!

Rewarming Phase Potassium, magnesium, and phosphate shift extravascularly/extracellularly out of cells. Rapidly rising serum potassium; risk of severe hyperkalemia. DISCONTINUE all potassium infusions prior to initiating rewarming. Monitor K+ q2–4h during rewarming.

Important

Continuing potassium replacement infusions during the rewarming phase is a common, life-threatening critical care error. Discontinue potassium infusions at least 4 to 8 hours prior to initiating rewarming to prevent fatal rebound hyperkalemia and secondary cardiac arrest.

  • Glycemic Management and Multimodal Neuroprognostication
  • Glycemic Targets

Hypothermia induces peripheral insulin resistance and inhibits pancreatic beta-cell insulin secretion, resulting in hyperglycemia. The recommended target is 140 to 180 mg/dL (7.8 to 10.0 mmol/L). Avoid tight glycemic control (80 to 110 mg/dL) due to high risk of severe hypoglycemia ( < 70 mg/dL <70\text{ mg/dL} < 70 mg/dL ), which exacerbates neuronal death in ischemic brain tissue.

Multimodal Neuroprognostication Timeline

Accurate neuroprognostication cannot be performed prematurely. Definitive neuroprognostication must be delayed until AT LEAST 72 hours after return to normothermia (typically 5 to 7 days post-cardiac arrest):

Confounders : Hypothermia and impaired drug clearance prolong the effects of sedatives, analgesics, and neuromuscular blockers. Neurological examination before 72 hours post-rewarming is fundamentally unreliable.

Multimodal Evaluation Components :

Clinical Exam : Bilaterally absent pupillary and corneal reflexes at ≥ 72 hours \ge 72\text{ hours} ≥ 72 hours post-rewarming.

Somatosensory Evoked Potentials (SSEP) : Bilateral absence of the N20 cortical potential wave.

Biomarkers : Marked, persistent elevations of serum neuron-specific enolase (NSE) .

Continuous EEG : Presence of highly malignant patterns (burst suppression, generalized suppression, non-reactive background, unreactive status epilepticus).

Neuroimaging : Diffuse brain edema with loss of gray-white matter differentiation on head CT (decreased gray-to-white ratio < 1.15 <1.15 < 1.15 ) or extensive diffusion restriction on brain MRI.